Q2 2026 saw double-digit revenue and EPS growth, driven by strong performance in HVP components, biologics, and GLP-1s, with margin expansion and robust cash flow. Full-year guidance was raised, reflecting continued momentum and successful recovery from a cyber incident.

Based on

This is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.